Board of Directors

Frederick W. Telling

Chairman of the Board

Dr. Telling has served as a Director since June 2010 and became Chairman in February 2011. Dr. Telling retired from Pfizer Inc. in June 2007 after 30 years of service as its Corporate Vice President and Vice President of Corporate Strategic Planning and Policy. He also serves as a director and member of the Compensation Committee and Audit Committee at Cell Therapeutics Inc., a public company based in Seattle, Washington. Dr. Telling holds a B.A. degree in History and Economics from Hamilton College and a MA degree in Industrial and Labor Relations and a PhD in Economics and Public Policy from Cornell University.

 

Committees

Committee Role
Audit Committee Member
Compensation Committee Member
Nominating and Corporate Governance Committee Member

Charles L. Pope

Director

Mr. Pope has served as a Director and Chairman of the Audit Committee since June 2010. Mr. Pope has also served as the Chairman of the Nominating and Corporate Governance Committee since July 2015. He was the Chief Financial Officer of Palm Bancorp, Inc. from June 2009 to April 2012 and from September 2007 through June 2009, Mr.Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. He currently serves on the board of directors of Inuvo, Inc. in Clearwater, Florida and served on the board of directors of Innovaro Inc. in Tampa, Florida until 2012. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida.

 

Committees

Committee Role
Audit Committee Chair
Nominating and Corporate Governance Committee Chair
Compensation Committee Member

Alan Dunton

Director

Dr. Alan W. Dunton has served as a Director since June 2010 and became Chairman of the Compensation Committee in July 2015. Dr. Dunton is also the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. He is on the Board of Directors at Targacept, Inc., Palatin Technologies, Inc., and Sancilio & Company, Inc. and holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine.

Committees

Committee Role
Compensation Committee Chair
Audit Committee Member
Nominating and Corporate Governance Committee Member

Robert Koski

Director

Mr. Koski has served as a Director since June 2009. Mr. Koski has practiced as an attorney with the Koski Firm, a sole proprietorship located in Atlanta, Georgia since 1992, where his practice includes litigation and tax law. Mr. Koski has also served as a partner in the Koski Family Limited Partnership, which beneficially owns a controlling interest in the Company, and as a director of the Koski Family Foundation since December 1996. He holds a B.A. degree in Philosophy and English from Colgate University, a JD from Emory School of Law and an LLM degree in Taxation and Litigation from Emory University. He is also the brother of one of our other Directors, Christine Koski.

 

Kim Murphy

Director

Ms. Murphy brings a wealth of vaccine industry knowledge and experience that are highly-relevant to the Company’s strategic acquisition of Noachis Terra, as well as the development of the Company’s other product candidates. Ms. Murphy is an accomplished leader and medical-industry professional with substantial experience in the vaccine development arena, having previously served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (“GSK”). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Ms. Murphy also managed a 2,000-employee vaccine development, sales, manufacturing, and distribution team and was responsible for the integration planning of GSK’s acquisition of Novartis AG’s vaccine division. Earlier in her career, she also worked in commercialization and marketing roles within Novartis Vaccines and Diagnostics Inc. and Merck & Co., Inc. Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, biotechnology industry groups, and academic and philanthropic societies. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph’s University.

Alan Joslyn, Ph.D.

President and Chief Executive Officer

Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and Director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-President Research and Development of Penwest Pharmaceuticals and also held senior drug development positions with Johnson & Johnson.